Market Newsdesk

 ATLANTA, July 24, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against EquipmentShare.com, Inc. (“EquipmentShare”) (NASDAQ: EQPT). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) EquipmentShare participated in additional undisclosed related party transactions; (2) EquipmentShare had not terminated or substantially reduced a number of the transactions with entities owned or controlled by the co-founders; and (3) as a result, EquipmentShare’s financial statements were materially misleading.

If you purchased EquipmentShare.com shares between January 23, 2026 and June 23, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected] or Marshall P. Dees, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/equipmentshare/ for more information. 

The deadline to ask the court to be appointed lead plaintiff in the case is September 21, 2026. 

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:
Marshall P. Dees, Esq. 
(888) 508-6832 (toll-free)
[email protected]

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market

Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA)

ISELIN, N.J., July 24, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD.

The approval establishes LYTENAVA™ as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States. For the first time, retina specialists and patients have access to an FDA-approved ophthalmic bevacizumab developed specifically for the eye and supported by rigorous clinical evidence, validated manufacturing, approved labeling, comprehensive quality systems, and ongoing FDA regulatory oversight. Additionally, the Company anticipates that the approval will provide LYTENAVA^TM with 12 years of Reference Product Exclusivity under the BPCIA.

Outlook Therapeutics believes this FDA approval establishes a new benchmark for ophthalmic bevacizumab and positions LYTENAVA™ to become the new FDA-approved standard for bevacizumab therapy in patients with wet AMD. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care.¹

“For more than two decades, bevacizumab has served as one of the most widely utilized anti-VEGF therapies in retina care despite the absence of an FDA-approved ophthalmic formulation. LYTENAVA™ fundamentally changes that landscape. Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics.

Mr. Jahr continued by saying, “Today’s approval represents a defining moment for Outlook Therapeutics and, more importantly, for the physicians and patients we have been working to serve. With the approval of LYTENAVA™, physicians now have access to the first FDA-approved ophthalmic bevacizumab developed specifically for the eye. We believe this approval has the potential to meaningfully advance patient care and establish LYTENAVA™ as an important new treatment option for retina specialists and wet AMD patients across the United States.”

“The retina community has been waiting a long time for access to an FDA-approved, ophthalmic formulation of bevacizumab to treat patients suffering from wet AMD in the United States,” added Firas M. Rahhal, MD, Chairman of Ophthalmology at Good Samaritan Hospital, Los Angeles, California. “It is exciting news that LYTENAVA™ will soon be an option for patients suffering from this disease.”

Wet AMD is a chronic, progressive retinal disease and one of the leading causes of severe vision loss among older adults worldwide.² Patients often require treatment over many years to preserve vision, making manufacturing consistency, product quality, and long-term reliability especially important throughout treatment.

LYTENAVA™ enters one of the world’s largest ophthalmology markets. The U.S. anti-VEGF retina market is estimated at approximately $8.5 billion annually, with millions of intravitreal injections administered every year.²

The Company is now executing the commercial launch of LYTENAVA™, including expanding reimbursement and patient support access, building an industry-leading, specialized retina commercial organization, supporting physicians nationwide, and establishing LYTENAVA™ as the trusted FDA-approved ophthalmic bevacizumab across the United States.

“FDA approval is the outcome we have been waiting for. Immediate commercial execution is our next mission,” added Mr. Jahr. “Everything we do from this point forward is focused on delivering LYTENAVA™ to physicians and patients, expanding access, and building what we believe can become the leading retina care franchise. We are incredibly excited about the opportunity ahead, not only for Outlook Therapeutics, but most importantly for the patients whose vision we strive to protect.”

Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end. The Company is committed to providing broad patient access support services through comprehensive reimbursement and patient assistance programs designed to help physicians integrate LYTENAVA™ into routine clinical practice for wet AMD.

<sup>1.    Citeline (2023), Global Data (2023) and Market Scope (2022).

2.    National Eye Institute. Age-Related Macular Degeneration (AMD). National Institutes of Health.</sup>

About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is the first ophthalmic formulation approved by the FDA. LYTENAVA™ (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD. In certain European Union Member States, LYTENAVA™ must receive pricing and reimbursement approval before it can be sold.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific for human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Important Safety Information and Indication
LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

Contraindications
LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Warnings and Precautions
Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Adverse Reactions
The most common adverse reaction (≥1%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). These are not all the possible side effects of LYTENAVA.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).

Please see the full US Prescribing Information for LYTENAVA here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding potential marketing approvals, Outlook Therapeutics plans to launch ONS-5010/LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community, new indications or labeling for LYTENAVA, Outlook Therapeutics development or future revenue plans for LYTENAVA generally, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the SEC on December 19, 2025, as supplemented by the Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
[email protected]

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP alerts investors in Verra Mobility Corporation (NASDAQ: VRRM) that a securities fraud class action lawsuit has been filed, and the firm has broadened its ongoing investigation into the company following an abrupt leadership transition. Investors suffering substantial losses are encouraged to contact the firm now.

Key VRRM Class Action Case Details

• Class Period: Feb. 24, 2026 – May 26, 2026 • Lead Plaintiff Deadline: Aug. 4, 2026
• Contact Hagens Berman to discuss your rights, evaluate recovery options, or seek appointment as lead plaintiff:	[email protected] 844-916-0895 www.hbsslaw.com/investor-fraud/vrrm

Core Allegations in Verra Mobility Lawsuit

The lawsuit alleges that Verra and certain executives made materially false and misleading statements and concealed critical adverse facts regarding the true state of the company’s relationship with Avis Budget Group. Defendants allegedly downplayed the risk of major rental car customers replacing Verra’s services with in-house or outsourced alternatives and misrepresented the likelihood of securing an Avis contract renewal.

Alleged Corrective Disclosure and Market Reaction

Date	Corrective Event	Stock Price Impact
May 26 – 27, 2026	Verra discloses the sudden Avis contract termination notice, slashes its 2026 outlook, announces operational restructuring, and initiates an internal review of negotiations	-71.0% single-day crash (Plummeting from $13.08 to close at $3.85 on May 27, wiping out roughly $1.4 billion in market cap)

View our latest video summary of the allegations: youtu.be/FVEw5XACoGA

Hagens Berman’s Expanded Investigation

In addition to investigating the lawsuit’s claims that Verra misled investors about the stability of key revenue streams and contract negotiations, Hagens Berman’s expanded investigation also focuses on the sudden June 1, 2026 departure of long-time CEO David Roberts—ending a 12-year tenure—and whether this leadership vacuum is causally linked to the catastrophic loss of the Avis contract and subsequent disclosures.

“Our investigation is focused on the extent to which and when Verra and its executives knew that renegotiations with Avis were far from constructive, as the May 26 surprise reveals,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

What Affected VRRM Investors Can Do

If you purchased or acquired Verra Mobility common stock between February 24, 2026, and May 26, 2026, and suffered losses, you have until August 4, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, or if you have knowledge that will assist the firm’s investigation, submit your information to Hagens Berman.

If you’d like more information and answers to other frequently asked questions about the Verra case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Verra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.

Class Period: Aug. 1, 2025 – May 15, 2026 Lead Plaintiff Deadline: Sept. 14, 2026 Visit:http://www.hbsslaw.com/investor-fraud/regn
Contact the Firm Now:	[email protected] 844-916-0895

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:

The litigation is focused on the propriety of Regeneron’s repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the “Study”).

The Study’s primary endpoint was progression-free survival (“PFS”) and Regeneron has characterized the combination as a “potential blockbuster.” “Events” – disease progression or death – determined the timing and statistical power of the primary PFS analysis.

The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study’s preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.

Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial’s achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are “because the test arms are performing well.”

The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that “t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months.”

One prominent analyst reportedly questioned whether the decision was made because, in contrast to management’s expressed confidence, the “underlying PFS benefit may be insufficient to show statistical significance.”

Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to “slow event rates,” occurred nearly six months ago, and was “submitted it to all the global regulatory authorities in November, December timeframe.”

Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the “trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS).”

“We’re focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn’t really there,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the suit.

If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Regeneron case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

Hagens Berman urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights.

Class Period: Jan. 14, 2025 – Apr. 26, 2026 Lead Plaintiff Deadline: Aug. 10, 2026 Visit:www.hbsslaw.com/investor-fraud/eras
Contact the Firm Now:	[email protected] 844-916-0895

The Alleged Erasca (ERAS) Securities Fraud:

Erasca’s public disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a “best-in-class” pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:

• Improper Preclinical Comparisons: Allegedly using flawed cross-study analyses to claim superiority over competing therapies, such as Revolution Medicines’ RMC-6236, without a reasonable basis.
• Concealing IP Disputes: Assuring investors that its IP was secure while allegedly failing to disclose that its practices exposed the company to significant patent infringement and trade secret misappropriation claims from Revolution Medicines.
• Downplaying Safety Risks: Touting favorable safety results while allegedly failing to adequately disclose the risks associated with ERAS-0015 clinical trials, which later surfaced following a patient death.

The Truth Emerges:

The complaint alleges on April 27–28, 2026, the artificial inflation in Erasca’s stock price was removed following two major disclosures:

1. Patent Infringement Allegations: The company disclosed a legal challenge from Revolution Medicines regarding patent infringement and trade secret misappropriation.
2. Adverse Clinical Data: Erasca reported preliminary data including a patient death linked to the ERAS-0015 trial.

These disclosures triggered a sharp stock decline, with shares falling significantly and wiping out over $2.8 billion in market capitalization.

Hagens Berman’s Investigation

“We’re investigating whether Erasca may have intentionally misled investors about ERAS-0015’s safety profile and about a potential moat in its particular, highly competitive cancer treatment space,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Lead Plaintiff Deadline

Investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, may be eligible to serve as the lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 10, 2026.

If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Erasca case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) — National shareholder rights firm Hagens Berman alerts investors in Roblox Corporation (NYSE: RBLX) that the alleged class period in the ongoing securities class action litigation has been expanded. A new lawsuit now covers investors who purchased or otherwise acquired Roblox common stock between October 31, 2024 through April 30, 2026, inclusive.

National shareholder rights firm Hagens Berman is investigating the legal claims that Roblox and its co-defendants violated the federal securities laws. The firm encourages Roblox investors who suffered substantial losses to submit your losses now.

Class Period: Oct. 31, 2024 – Apr. 30, 2026
Lead Plaintiff Deadline: Aug. 7, 2026
Visit: www.hbsslaw.com/investor-fraud/rblx
Contact the Firm Now:	[email protected]
	844-916-0895

Roblox Corporation (RBLX) Securities Class Action:

The primary focus of the litigation is on the propriety of Roblox’s disclosures about its commitment toward protecting the safety of young users of its platform and the recent the impact on its business and prospects of the age-check verification rollout aimed at increasing safety within certain social features on its platform. The rollout began in November 2025.

During the Class Period, Roblox and its senior management have assured investors that “safety would be paramount[,]” “building safety into our products has been a huge effort[,]” and “[o]ur approach to safety includes multiple proactive measures as well as parental controls[.]” They have also emphasized that “b]ecause our Platform includes children aged 5 and over, our safety and civility policies are purpose-built to be strict.”

Investors slowly learned the truth through a series of disclosures beginning on October 30, 2025. That day, the Company revealed that it would be instituting enhanced age verification technology globally beginning in January 2026. On this news, the price of the Company’s common stock declined 16% from $133.74 per share to $113.00 per share, wiping out $13 billion in market value.

Then, on April 30, 2026, Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance (reflecting ongoing shrinkage in DAU growth), and severely cut its 2026 bookings growth midpoint from 24% to just 10%, investors glimpsed what was really going on.

Roblox said just 51% of its global DAUs age checked and also said that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.

“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Roblox and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) — National shareholder rights firm Hagens Berman is actively investigating claims in a pending securities class action alleging securities law violations at Black Rock Coffee Bar, Inc. (NASDAQ: BRCB). The suit alleges the company and its senior executives provided false and misleading information to investors regarding the efficacy of its expansion strategy during its September 2025 Initial Public Offering (IPO) and throughout the subsequent months.

REPORT YOUR BRCB LOSSES TO HBSS NOW

Lead Plaintiff Deadline: Aug. 17, 2026
Class Period: Sep. 12, 2025 – May 12, 2026
Visit: www.hbsslaw.com/investor-fraud/brcb
Contact the Firm Now:	[email protected]
	844-916-0895

Black Rock Coffee Bar, Inc. (BRCB) Securities Class Action:

The complaint alleges that Black Rock Coffee’s IPO documents and subsequent financial reports touted a “concentric circle” expansion model, assuring investors that the company could increase store density with “limited sales transfer” (cannibalization). The suit alleges these assurances were materially false when made.

Specifically, the complaint contends that:

• Aggressive Cannibalization: New store openings were actively shifting customer traffic and revenue away from existing high-volume locations.
• Misleading Growth Metrics: Management continued to project aggressive growth targets while withholding internal data indicating that store density was creating a significant “sales transfer” headwind to same-store sales growth.
• Failure of Internal Controls: The company’s failure to disclose these operational headwinds until the May 12, 2026, earnings report evidences a disregard for transparent financial reporting standards.

By the time the lawsuit was filed on June 18, 2026, Black Rock Coffee shares had steadily declined to $7.72, or over 61% below the IPO price.

“The suit alleges that investors were sold a narrative of seamless, high-density growth,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the claims in the pending suit. “Our investigation is focused on determining when Black Rock management knew or should have known that their expansion strategy was eroding revenue at existing locations and when that information should have been shared with shareholders.”

Investor Rights and Lead Plaintiff Deadline

Investors who purchased or acquired Black Rock Coffee common stock traceable to the September 2025 IPO through May 12, 2026, may be eligible to serve as lead plaintiff. The court-imposed deadline to move for appointment as lead plaintiff is August 17, 2026.

• Submit your losses now to HBSS Now
• Contact Our Attorneys: [email protected]
• HBSS Investor Hotline: 844-916-0895

If you’d like more information and answers to other frequently asked questions about the Black Rock Coffee case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Black Rock Coffee should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. 

Contact:

Reed Kathrein, 844-916-0895

WHITE PLAINS, N.Y., July 24, 2026 (GLOBE NEWSWIRE) — NorthEast Community Bancorp, Inc. (Nasdaq: NECB) (the “Company”), the parent holding company of NorthEast Community Bank (the “Bank”), reported net income of $9.8 million, or $0.75 per basic share and $0.72 per diluted share, for the three months ended June 30, 2026 compared to net income of $11.2 million, or $0.85 per basic share and $0.82 per diluted share, for the three months ended June 30, 2025. In addition, the Company reported net income of $19.7 million, or $1.50 per basic share and $1.46 per diluted share, for the six months ended June 30, 2026 compared to net income of $21.7 million, or $1.65 per basic share and $1.60 per diluted share, for the six months ended June 30, 2025.

Kenneth A. Martinek, Chairman of the Board and Chief Executive Officer, stated “We are again pleased to report continued strong performance throughout our entire loan portfolio. We continue our laser focus on construction lending in high demand, high absorption submarkets in the Bronx, Rockland, Orange, and Sullivan Counties.”

“Demand for construction loans throughout these submarkets continues to demonstrate robust growth and we look forward to continuing to meet this growing demand going forward. At June 30, 2026, construction loan commitments and loans-in-process outstanding increased by approximately 38.9% as compared to the second quarter of 2025, with over $883 million in total unfunded loan commitments outstanding, and representing a 30.0% increase over the amount of such total commitments outstanding at December 31, 2025.”

Highlights for the three months and six months ended June 30, 2026 are as follows:

• Performance metrics continue to be strong with a return on average total assets ratio of 1.95%, a return on average shareholders’ equity ratio of 10.81%, and an efficiency ratio of 41.99% for the three months ended June 30, 2026. For the six months ended June 30, 2026, the Company reported a return on average total assets ratio of 1.96%, a return on average shareholders’ equity ratio of 10.97%, and an efficiency ratio of 42.81%.
• Asset quality metrics continue to remain strong with no non-performing loans at either June 30, 2026 or December 31, 2025, and a non-performing assets to total assets ratio of 0.00% at both June 30, 2026 and at December 31, 2025. Our allowance for credit losses related to loans totaled $4.8 million, or 0.25% of total loans at June 30, 2026 compared to $4.7 million, or 0.25% of total loans at December 31, 2025.
• Total stockholders’ equity increased by $10.9 million, or 3.1%, to $362.6 million, or 17.14% of total assets as of June 30, 2026 from $351.7 million, or 17.04% of total assets as of December 31, 2025.

Balance Sheet Summary

Total assets increased $51.7 million, or 2.5%, to $2.1 billion at June 30, 2026, from $2.1 billion at December 31, 2025. The increase in assets was primarily due to an increase in net loans of $59.4 million, partially offset by a decrease in cash and cash equivalents of $7.8 million.

Cash and cash equivalents decreased $7.8 million, or 9.6%, to $73.4 million at June 30, 2026 from $81.2 million at December 31, 2025. The decrease in cash and cash equivalents partially funded the increase of $59.4 million in net loans.

Equity securities increased $757,000, or 2.8%, to $27.3 million at June 30, 2026 from $26.6 million at December 31, 2025. The increase in equity securities was attributable to the purchase of $1.0 million in equity securities during the six months ended June 30, 2026, partially offset by market depreciation of $243,000 due to market interest rate volatility during the six months ended June 30, 2026.

Securities held-to-maturity decreased $564,000, or 3.1%, to $17.8 million at June 30, 2026 from $18.3 million at December 31, 2025 due to pay-downs of various investment securities and an increase of $9,000 to the allowance for credit losses for held-to-maturity securities, partially offset by the purchase of $470,000 in municipal securities.

Loans, net of the allowance for credit losses, increased $59.4 million, or 3.2%, to $1.9 billion at June 30, 2026 from $1.9 billion at December 31, 2025. The increase in loans consisted of an increase of $67.2 million in construction loans, partially offset by decreases of $4.9 million in multi-family loans, $2.2 million in non-residential loans, $200,000 in mixed-use loans, $69,000 in one-to-four family loans, $23,000 in consumer loans, and $3,000 in commercial and industrial loans.

During the six months ended June 30, 2026, we originated loans totaling $653.2 million, which includes commitments and funded loans, consisting primarily of $606.7 million in construction loans, $25.1 million in commercial and industrial loans, $20.8 million in multi-family loans, and $675,000 in mixed-use loans. The $606.7 million in construction loans had $262.7 million, or 43.3%, disbursed at loan closing, with the remaining funds to be disbursed over the terms of the construction loans. These disbursements were offset by normal pay-downs and principal reductions as construction projects were completed and either condominium units were sold to end buyers or multi-family rental buildings were refinanced by other financial institutions. The commercial and industrial loans had $19.0 million, or 75.7%, disbursed at loan closing as of June 30, 2026.

The allowance for credit losses related to loans was $4.6 million at June 30, 2026 and December 31, 2025. The allowance for credit losses related to loans had a provision for credit losses totaling $568,000 and charge-offs totaling $547,000. The provision for credit losses totaling $568,000 was due to an increase in the loan portfolio and a slight increase in the remaining terms of the loan portfolio.

The allowance for credit losses for off-balance sheet commitments increased $284,000, or 32.3%, to $1.2 million at June 30, 2026 from $879,000 at December 31, 2025 due primarily to an increase of $204.2 million, or 30.0%, in off-balance sheet commitments from December 31, 2025 to June 30, 2026.

The allowance for credit losses for held-to-maturity securities increased $9,000, or 7.1%, to $135,000 at June 30, 2026 from $126,000 at December 31, 2025 due to an increase in our municipal bond portfolio.

Premises and equipment decreased $356,000, or 1.4%, to $25.0 million at June 30, 2026 from $25.4 million at December 31, 2025 primarily due to the amortization of fixed assets.

Federal Home Loan Bank stock increased by $133,000, or 32.4%, to $543,000 at June 30, 2026 from $410,000 at December 31, 2025 primarily due to an increase in our mortgage-related assets.

Bank owned life insurance (“BOLI”) increased $364,000, or 1.4%, to $26.8 million at June 30, 2026 from $26.4 million at December 31, 2025 due to increases in the BOLI cash value.

Accrued interest receivable decreased $39,000, or 0.3%, to $12.2 million at June 30, 2026 from $12.2 million at December 31, 2025 due to a decrease in the yield in the loan portfolio.

Property held for investment was $1.3 million at both June 30, 2026 and December 31, 2025.

Right of use assets — operating decreased $360,000, or 7.7%, to $4.3 million at June 30, 2026 from $4.7 million at December 31, 2025, primarily due to depreciation of the right of use assets.

Other assets increased $117,000, or 1.1%, to $11.1 million at June 30, 2026 from $11.0 million at December 31, 2025 due to an increase of $725,000 in suspense accounts, partially offset by decreases of $528,000 in tax assets and $90,000 in prepaid expenses.

Total deposits decreased $80.4 million, or 5.0%, to $1.5 billion at June 30, 2026 from $1.6 billion at December 31, 2025. The decrease in deposits was primarily due to decreases in certificates of deposit of $190.8 million, or 21.2%, and savings account balances of $10.6 million, or 7.5%, partially offset by increases in NOW/money market accounts of $67.5 million, or 22.3% and non-interest bearing deposits of $53.5 million, or 19.7%.

The decrease of $190.8 million in certificates of deposit consisted of decreases of $129.0 million, or 34.9%, in brokered certificates of deposit, $38.3 million, or 56.6%, in non-brokered listing services certificates of deposit, and $23.4 million, or 5.3% in retail certificates of deposit.

The decrease in brokered certificates of deposit and non-brokered listing services certificates of deposit was due to management’s strategy to reduce the cost of funds by “calling” higher rate brokered deposits on their call dates and to rely less on brokered deposits and non-brokered listing service deposits. The decrease in retail certificates of deposit was due to a shift in deposits to our retail high yield money market accounts.

Advance payments by borrowers for taxes and insurance increased $210,000, or 8.9%, to $2.6 million at June 30, 2026 from $2.4 million at December 31, 2025 due primarily to accumulation of real estate tax payments from borrowers.

Borrowings increased $120.0 million, or 171.4%, to $190.0 million at June 30, 2026 from $70.0 million at December 31, 2025 due primarily to management’s strategy to reduce the cost of funds and lessen reliance on brokered deposits and non-brokered listing service deposits.

Lease liability – operating decreased $329,000, or 6.9%, to $4.5 million at June 30, 2026 from $4.8 million at December 31, 2025, primarily due to the amortization of the lease liability.

Accounts payable and accrued expenses increased $980,000, or 6.0%, to $18.6 million at June 30, 2026 from $17.3 million at December 31, 2025 due primarily to increases in accounts payable of $1.3 million, suspense account – loan closings of $322,000, deferred compensation of $291,000, the allowance for credit losses for off-balance sheet commitments of $284,000, and accrued interest expense of $107,000, partially offset by a decrease in accrued expenses of $1.0 million.

Stockholders’ equity increased $10.9 million, or 3.1% to $362.6 million at June 30, 2026, from $351.7 million at December 31, 2025. The increase in stockholders’ equity was due to net income of $19.7 million for the six months ended June 30, 2026, the amortization expense of $1.1 million relating to restricted stock and stock options granted under the Company’s 2022 Equity Incentive Plan, an increase of $371,000 in earned employee stock ownership plan shares coupled with a reduction of $261,000 in unearned employee stock ownership plan shares, $37,000 in stock options exercised, and $25,000 in other comprehensive income. These increases were offset by dividends declared of $6.0 million and stock repurchases and excise taxes of $4.7 million.

Results of Operations for the Three Months Ended June 30, 2026 and 2025

Net Interest Income

Net interest income was $24.7 million for the three months ended June 30, 2026, as compared to $25.1 million for the three months ended June 30, 2025. The decrease in net interest income of $424,000, or 1.7%, was primarily due to a decrease in interest income that exceeded a decrease in interest expense caused by a decrease in the yield on interest-earning assets that exceeded the decrease in the cost of funds for interest-bearing liabilities.

Total interest and dividend income decreased $2.0 million, or 5.2%, to $36.1 million for the three months ended June 30, 2026 from $38.1 million for the three months ended June 30, 2025. The decrease in interest and dividend income was due to a decrease in the yield on interest-earning assets by 60 basis points from 8.11% for the three months ended June 30, 2025 to 7.51% for the three months ended June 30, 2026, partially offset by an increase in the average balance of interest-earning assets of $43.8 million, or 2.3%, to $1.9 billion for the three months ended June 30, 2026 from $1.9 billion for the three months ended June 30, 2025.

Interest expense decreased $1.6 million, or 12.0%, to $11.4 million for the three months ended June 30, 2026 from $13.0 million for the three months ended June 30, 2025. The decrease in interest expense was due to a decrease in the cost of interest-bearing liabilities by 43 basis points from 3.88% for the three months ended June 30, 2025 to 3.45% for the three months ended June 30, 2026. The decrease in interest expense was also due to a decrease in the average balance of interest-bearing liabilities of $16.0 million, or 1.2%, to $1.3 billion for the three months ended June 30, 2026 from $1.3 billion for the three months ended June 30, 2025.

Our net interest margin decreased 21 basis points, or 3.9%, to 5.14% for the three months ended June 30, 2026 compared to 5.35% for the three months ended June 30, 2025. The decrease in the net interest margin was due to a 75 basis points decrease in the Federal Funds rate from September 2025 to December 2025 that resulted in a decrease in the yield on interest-earning assets, partially offset by a smaller decrease in the cost of funds on interest-bearing liabilities.

Credit Loss Expense

The Company recorded credit loss expense of $860,000 for the three months ended June 30, 2026 compared to no credit loss expense for the three months ended June 30, 2025.

The credit loss expense of $860,000 for the three months ended June 30, 2026 was comprised of credit loss expense for loans of $680,000, credit loss expense for off-balance sheet commitments of $171,000, and credit loss expense for held-to-maturity securities of $9,000. The credit loss expense for loans of $680,000 for the three months ended June 30, 2026 was primarily due to an increase in the loan portfolio. The credit loss expense for off-balance sheet commitments of $171,000 for the three months ended June 30, 2026 was primarily due to an increase in unfunded off-balance sheet commitments. The credit loss expense for held-to-maturity securities of $9,000 for the three months ended June 30, 2026 was primarily due to an increase in the municipal bond portfolio.

With respect to the allowance for credit losses for loans, we charged-off $520,000 during the quarter ended June 30, 2026, as compared to charge-offs of $485,000 during the quarter ended June 30, 2025. The charge-offs during the quarter ended June 30, 2026 comprised of $500,000 against a commercial and industrial loan and $20,000 against various unpaid overdrafts in our demand deposit accounts. The charge-offs during the quarter ended June 30, 2025 were against various unpaid overdrafts in our demand deposit accounts.

We recorded no recoveries during the quarter ended June 30, 2026 compared to recoveries of $82,000 during the quarter ended June 30, 2025. The recoveries of $82,000 during the quarter ended June 30, 2025 comprised of recoveries from a previously charged-off unpaid overdraft on a demand deposit account.

Non-Interest Income

Non-interest income for the three months ended June 30, 2026 was $642,000 compared to non-interest income of $858,000 for the three months ended June 30, 2025. The decrease of $216,000, or 25.2%, in total non-interest income was primarily due to decreases of $173,000 in unrealized gain/(loss) on equity securities and $62,000 in other loan fees and service charges, partially offset by increases of $15,000 in BOLI income and $4,000 in miscellaneous other non-interest income.

The decrease in unrealized gain/(loss) on equity securities was due to an unrealized loss of $122,000 on equity securities during the quarter ended June 30, 2026 compared to an unrealized gain of $51,000 on equity securities during the quarter ended June 30, 2025. The unrealized loss of $122,000 and unrealized gain of $51,000 on equity securities during the quarters ended June 30, 2026 and 2025, respectively, were due to market interest rate volatility during both periods.

The decrease of $62,000 in other loan fees and service charges was due to decreases of $82,000 in loan service charges and fees, partially offset by an increase of $20,000 in ATM/debit card/ACH fees. The increase of $15,000 in BOLI income was due to an increase in the yield on BOLI assets. The increase of $4,000 in miscellaneous other non-interest income was due to increases in miscellaneous operating income during the quarter.

Non-Interest Expense

Non-interest expense increased $110,000, or 1.0%, to $10.6 million for the three months ended June 30, 2026 from $10.5 million for the three months ended June 30, 2025. The increase resulted primarily from increases of $291,000 in other operating expense, $166,000 in salaries and employee benefits, and $44,000 in occupancy expense, partially offset by decreases of $247,000 in real estate owned expense, $79,000 in advertising expense, $33,000 in outside data processing expense, and $32,000 in equipment expense.

Income Taxes

We recorded income tax expense of $4.0 million and $4.3 million for the three months ended June 30, 2026 and 2025, respectively. For the three months ended June 30, 2026, we had approximately $252,000 in tax exempt income, compared to approximately $210,000 in tax exempt income for the three months ended June 30, 2025. Our effective income tax rate was 29.1% for the three months ended June 30, 2026 compared to 27.6% for the three months ended June 30, 2025.

Results of Operations for the Six Months Ended June 30, 2026 and 2025

Net Interest Income

Net interest income was $48.8 million for the six months ended June 30, 2026 as compared to $49.3 million for the six months ended June 30, 2025. The decrease in net interest income of $555,000, or 1.1%, was primarily due to a decrease in interest income that exceeded a decrease in interest expense and a decrease in the yield on interest earning assets, partially offset by a smaller decrease in the cost of funds for interest bearing liabilities.

Total interest and dividend income decreased $4.2 million, or 5.5%, to $72.0 million for the six months ended June 30, 2026 from $76.2 million for the six months ended June 30, 2025. The decrease in interest and dividend income was due to a decrease in the yield on interest earning assets by 60 basis points from 8.08% for the six months ended June 30, 2025 to 7.48% for the six months ended June 30, 2026, partially offset by an increase in the average balance of interest earning assets of $39.5 million, or 2.1%, to $1.9 billion for the six months ended June 30, 2026 from $1.9 billion for the six months ended June 30, 2025.

Interest expense decreased $3.7 million, or 13.6%, to $23.2 million for the six months ended June 30, 2026 from $26.9 million for the six months ended June 30, 2025. The decrease in interest expense was due to a decrease in the cost of interest bearing liabilities by 51 basis points from 3.97% for the six months ended June 30, 2025 to 3.46% for the six months ended June 30, 2026 and a decrease in average interest bearing liabilities of $13.0 million, or 1.0%, to $1.3 billion for the six months ended June 30, 2026 from $1.4 billion for the six months ended June 30, 2025.

Net interest margin decreased 17 basis points, or 3.2%, to 5.06% for the six months ended June 30, 2026 compared to 5.23% for the six months ended June 30, 2025. The decrease in the net interest margin was due to a 75 basis points decrease in the Federal Funds rate from September 2025 to December 2025 that resulted in a decrease in the yield on interest-earning assets, partially offset by a smaller decrease in the cost of funds on interest-bearing liabilities.

Credit Loss Expense

The Company recorded a credit loss expense of $860,000 for the six months ended June 30, 2026 compared to a credit loss expense of $237,000 for the six months ended June 30, 2025. The credit loss expense of $860,000 for the six months ended June 30, 2026 was comprised of credit loss expense for loans of $568,000, credit loss expense for off-balance sheet commitments of $283,000, and credit loss expense for held-to-maturity securities of $9,000. The credit loss expense of $237,000 for the six months ended June 30, 2025 was comprised of credit loss expense for loans of $62,000 and credit loss expense for off-balance sheet commitments of $175,000.

The credit loss expense for loans of $568,000 for the six months ended June 30, 2026 was primarily due to an increase in the loan portfolio. The credit loss expense for off-balance sheet commitments of $283,000 for the six months ended June 30, 2026 was primarily due to an increase in unfunded off-balance sheet commitments. The credit loss expense for held-to-maturity securities of $9,000 for the six months ended June 30, 2026 was primarily due to an increase in the municipal bond portfolio.

The credit loss expense for loans of $62,000 for the six months ended June 30, 2025 was primarily due to an increase in the multi-family loan portfolio. The credit loss expense for off-balance sheet commitments of $175,000 for the six months ended June 30, 2025 was primarily due to an increase in unfunded off-balance sheet commitments.

With respect to the allowance for credit losses for loans, we charged-off $547,000 during the six months ended June 30, 2026 as compared to charge-offs of $602,000 during the six months ended June 30, 2025. The charge-offs during the six months ended June 30, 2026 comprised of $500,000 against a commercial and industrial loan and $47,000 against various unpaid overdrafts in our demand deposit accounts. The charge-offs during the six months ended June 30, 2025 were against various unpaid overdrafts in our demand deposit accounts.

We recorded no recoveries during the six months ended June 30, 2026 compared to recoveries of $434,000 during the six months ended June 30, 2025. The recoveries of $434,000 during the six months ended June 30, 2025 comprised of recoveries of $350,000 with respect to a previously charged-off non-residential mortgage loan and $84,000 from previously charged-off unpaid overdrafts on demand deposit accounts.

Non-Interest Income

Non-interest income for the six months ended June 30, 2026 was $1.4 million compared to non-interest income of $2.1 million for the six months ended June 30, 2025. The decrease of $655,000, or 31.3%, in total non-interest income was primarily due to decreases of $594,000 in unrealized gain/(loss) on equity securities and $133,000 in other loan fees and service charges, partially offset by increases of $45,000 in miscellaneous other non-interest income and $27,000 in BOLI income.

The decrease in unrealized gain on equity securities was due to an unrealized loss of $243,000 on equity securities during the six months ended June 30, 2026 compared to an unrealized gain of $351,000 on equity securities during the six months ended June 30, 2025. Both the unrealized loss of $243,000 on equity securities during the 2026 period and the unrealized gain of $351,000 on equity securities during the 2025 period were due to market interest rate volatility during both periods.

The decrease of $133,000 in other loan fees and service charges was due to a decrease of $226,000 in other loan fees and loan servicing fees, partially offset by an increase of $92,000 in ATM/debit card/ACH fees. The increase of $45,000 in miscellaneous other non-interest income was due to general accrual adjustments during the first quarter of 2026. The increase in BOLI income of $27,000 was due to an increase in the yield on BOLI assets.

Non-Interest Expense

Non-interest expense increased $371,000, or 1.8%, to $21.5 million for the six months ended June 30, 2026 from $21.1 million for the six months ended June 30, 2025. The increase resulted primarily from increases of $406,000 in salaries and employee benefits, $208,000 in other operating expense, $172,000 in occupancy expense, and $27,000 in outside data processing expense, partially offset by decreases of $277,000 in real estate owned expense, $139,000 in advertising expense, and $26,000 in equipment expense.

Income Taxes

We recorded income tax expense of $8.1 million and $8.3 million for the six months ended June 30, 2026 and 2025, respectively. For the six months ended June 30, 2026, we had approximately $500,000 in tax exempt income, compared to approximately $415,000 in tax exempt income for the six months ended June 30, 2025. Our effective income tax rates were 29.1% and 27.7% for the six months ended June 30, 2026 and 2025, respectively.

Asset Quality

We had no non-performing assets at June 30, 2026 and December 31, 2025. Our ratio of non-performing assets to total assets was 0.00% at June 30, 2026 and December 31, 2025.

The Company’s allowance for credit losses related to loans was $4.8 million, or 0.25% of total loans as of June 30, 2026, compared to $4.7 million, or 0.25% of total loans as of December 31, 2025. Based on a review of the loans that were in the loan portfolio at June 30, 2026, management believes that the allowance for credit losses related to loans is maintained at a level that represents its best estimate of expected losses in the loan portfolio.

In addition, at June 30, 2026, the Company’s allowance for credit losses related to off-balance sheet commitments totaled $1.2 million and the allowance for credit losses related to held-to-maturity debt securities totaled $135,000.

Capital

The Company’s total stockholders’ equity to assets ratio was 17.14% as of June 30, 2026. At June 30, 2026, the Company had the ability to borrow $633.0 million from the Federal Reserve Bank of New York and $8.0 million from Atlantic Community Bankers Bank.

The Bank’s capital position remains strong relative to current regulatory requirements and the Bank is considered a well-capitalized institution under the Prompt Corrective Action framework. As of June 30, 2026, the Bank had a tier 1 leverage capital ratio of 17.32% and a total risk-based capital ratio of 15.31%.

The Company commenced its third stock repurchase program on December 10, 2025 whereby the Company will repurchase 1,400,435, or 10%, of the Company’s issued and outstanding common stock. As of June 30, 2026, the Company had repurchased 239,894 shares of common stock under its third repurchase program, at a cost of $5.6 million, including commission costs and Federal excise taxes.

About NorthEast Community Bancorp

NorthEast Community Bancorp, headquartered at 325 Hamilton Avenue, White Plains, New York 10601, is the holding company for NorthEast Community Bank, which conducts business through its eleven branch offices located in Bronx, New York, Orange, Rockland, and Sullivan Counties in New York and Essex, Middlesex, and Norfolk Counties in Massachusetts and three loan production offices located in New City, New York, White Plains, New York, and Danvers, Massachusetts. For more information about NorthEast Community Bancorp and NorthEast Community Bank, please visit www.necb.com.

Forward Looking Statement

This press release contains certain forward-looking statements. Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause actual results to differ materially from expected results include, but are not limited to, changes in market interest rates, regional and national economic conditions (including higher inflation or recessionary conditions and their impact on regional and national economic conditions), legislative and regulatory changes, changes relating to rent regulation and housing, including recent legislative action in New York City to freeze rents on certain rent-regulated properties, monetary and fiscal policies of the United States government, including policies of the United States Treasury and the Federal Reserve Board, the impacts of tariffs, sanctions and other trade policies of the United States and its global trading counterparts, the impact of changing political conditions or federal government shutdowns, the quality and composition of the loan or investment portfolios, demand for loan products, decreases in deposit levels necessitating increased borrowing to fund loans and securities, competition, demand for financial services in NorthEast Community Bank’s market area, changes in the real estate market values in NorthEast Community Bank’s market area, the impact of failures or disruptions in or breaches of the Company’s operational or security systems, data or infrastructure, or those of third parties, including as a result of cyberattacks or campaigns, and changes in relevant accounting principles and guidelines. Additionally, other risks and uncertainties may be described in our annual and quarterly reports filed with the U.S. Securities and Exchange Commission (the “SEC”), which are available through the SEC’s website located at www.sec.gov. These risks and uncertainties should be considered in evaluating any forward-looking statements and undue reliance should not be placed on such statements. Except as required by applicable law or regulation, the Company does not undertake, and specifically disclaims any obligation, to release publicly the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of the statements or to reflect the occurrence of anticipated or unanticipated events.

CONTACT:	Kenneth A. Martinek Chairman and Chief Executive Officer
PHONE:	(914) 684-2500

NORTHEAST COMMUNITY BANCORP, INC. CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION (Unaudited)
		June 30,				December 31,
		2026				2025
		(In thousands, except share
		and per share amounts)
ASSETS
Cash and amounts due from depository institutions		$	9,473			$	10,456
Interest-bearing deposits			63,941				70,719
Total cash and cash equivalents			73,414				81,175
Certificates of deposit			100				100
Equity securities			27,327				26,570
Securities held-to-maturity (net of allowance for credit losses of $135 and $126, respectively )			17,751				18,315
Loans receivable			1,919,908				1,860,066
Deferred loan (fees) costs, net			(149	)			268
Allowance for credit losses			(4,752	)			(4,731	)
Net loans			1,915,007				1,855,603
Premises and equipment, net			25,021				25,377
Investments in restricted stock, at cost			543				410
Bank owned life insurance			26,797				26,433
Accrued interest receivable			12,189				12,228
Property held for investment			1,315				1,334
Right of Use Assets – Operating			4,296				4,656
Right of Use Assets – Financing			342				343
Other assets			11,081				10,964
Total assets		$	2,115,183			$	2,063,508
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities:
Deposits:
Non-interest bearing		$	325,415			$	271,924
Interest bearing			1,211,128				1,344,977
Total deposits			1,536,543				1,616,901
Advance payments by borrowers for taxes and insurance			2,562				2,352
Borrowings			190,000				70,000
Lease Liability – Operating			4,467				4,796
Lease Liability – Financing			454				434
Accounts payable and accrued expenses			18,589				17,325
Total liabilities			1,752,615				1,711,808
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued or outstanding		$	—			$	—
Common stock, $0.01 par value; 75,000,000 shares authorized; 13,771,951 shares and 13,963,432 shares outstanding, respectively			138				140
Additional paid-in capital			108,383				111,575
Unearned Employee Stock Ownership Plan (“ESOP”) shares			(4,957	)			(5,218	)
Retained earnings			258,746				244,970
Accumulated other comprehensive gain			258				233
Total stockholders’ equity			362,568				351,700
Total liabilities and stockholders’ equity		$	2,115,183			$	2,063,508

NORTHEAST COMMUNITY BANCORP, INC. CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
		Three Months Ended June 30,							Six Months Ended June 30,
		2026				2025			2026				2025
		(In thousands, except per share amounts)							(In thousands, except per share amounts)
INTEREST INCOME:
Loans		$	35,174			$	36,740		$	70,216			$	73,622
Interest-earning deposits			554				1,027			1,156				2,108
Securities			332				272			657				516
Total Interest Income			36,060				38,039			72,029				76,246
INTEREST EXPENSE:
Deposits			10,610				12,053			22,012				25,986
Borrowings			790				902			1,213				902
Financing lease			10				10			20				20
Total Interest Expense			11,410				12,965			23,245				26,908
Net Interest Income			24,650				25,074			48,784				49,338
Provision for credit loss			860				—			860				237
Net Interest Income after Provision for Credit Loss			23,790				25,074			47,924				49,101
NON-INTEREST INCOME:
Other loan fees and service charges			549				611			1,218				1,351
Earnings on bank owned life insurance			185				170			364				336
Unrealized (loss) gain on equity securities			(122	)			51			(243	)			351
Other			30				26			99				55
Total Non-Interest Income			642				858			1,438				2,093
NON-INTEREST EXPENSES:
Salaries and employee benefits			5,817				5,650			11,989				11,583
Occupancy expense			787				743			1,661				1,489
Equipment			221				253			444				470
Outside data processing			725				758			1,521				1,494
Advertising			43				123			86				225
Real estate owned expense			–				247			–				277
Other			3,026				2,734			5,797				5,589
Total Non-Interest Expenses			10,619				10,508			21,498				21,127
INCOME BEFORE PROVISION FOR INCOME TAXES			13,813				15,424			27,864				30,067
PROVISION FOR INCOME TAXES			4,018				4,254			8,117				8,330
NET INCOME		$	9,795			$	11,170		$	19,747			$	21,737

NORTHEAST COMMUNITY BANCORP, INC. SELECTED CONSOLIDATED FINANCIAL DATA (Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
		(In thousands, except per share amounts)								(In thousands, except per share amounts)
Per share data:
Earnings per share – basic		$	0.75			$	0.85			$	1.50			$	1.65
Earnings per share – diluted			0.72				0.82				1.46				1.60
Weighted average shares outstanding – basic			13,135				13,216				13,155				13,204
Weighted average shares outstanding – diluted			13,538				13,568				13,533				13,563
Performance ratios/data:
Return on average total assets			1.95	%			2.27	%			1.96	%			2.20	%
Return on average shareholders’ equity			10.81	%			13.37	%			10.97	%			13.18	%
Net interest income		$	24,650			$	25,074			$	48,784			$	49,338
Net interest margin			5.14	%			5.35	%			5.06	%			5.23	%
Efficiency ratio			41.99	%			40.52	%			42.81	%			41.08	%
Net charge-off ratio			0.11	%			0.09	%			0.06	%			0.01	%
Loan portfolio composition:										June 30, 2026				December 31, 2025
One-to-four family										$	3,046			$	3,114
Multi-family											301,628				306,508
Mixed-use											24,997				25,197
Total residential real estate											329,671				334,819
Non-residential real estate											36,247				38,463
Construction											1,403,562				1,336,329
Commercial and industrial											150,394				150,397
Consumer											34				58
Gross loans											1,919,908				1,860,066
Deferred loan (fees) cost, net											(149	)			268
Total loans										$	1,919,759			$	1,860,334
Asset quality data:
Loans past due over 90 days and still accruing										$	–			$	–
Non-accrual loans											–				–
Total non-performing assets										$	—			$	—
Allowance for credit losses to total loans											0.25	%			0.25	%
Allowance for credit losses to non-performing loans											0.00	%			0.00	%
Non-performing loans to total loans											0.00	%			0.00	%
Non-performing assets to total assets											0.00	%			0.00	%
Bank’s Regulatory Capital ratios:
Total capital to risk-weighted assets											15.31	%			15.62	%
Common equity tier 1 capital to risk-weighted assets											15.05	%			15.36	%
Tier 1 capital to risk-weighted assets											15.05	%			15.36	%
Tier 1 leverage ratio											17.32	%			16.39	%

NORTHEAST COMMUNITY BANCORP, INC. NET INTEREST MARGIN ANALYSIS (Unaudited)
		Three Months Ended June 30, 2026										Three Months Ended June 30, 2025
		Average				Interest			Average			Average				Interest			Average
		Balance				and dividend			Yield			Balance				and dividend			Yield
		(In thousands, except yield/cost information)										(In thousands, except yield/cost information)
Loan receivable gross		$	1,823,222			$	35,174		7.72	%		$	1,754,363			$	36,740		8.38	%
Securities			45,375				324		2.86	%			37,839				265		2.80	%
Federal Home Loan Bank stock			536				8		5.97	%			438				7		6.39	%
Other interest-earning assets			50,466				554		4.39	%			83,135				1,027		4.94	%
Total interest-earning assets			1,919,599				36,060		7.51	%			1,875,775				38,039		8.11	%
Allowance for credit losses			(4,594	)									(5,122	)
Non-interest-earning assets			93,251										95,651
Total assets		$	2,008,256									$	1,966,304
Interest-bearing demand deposit		$	346,797			$	2,652		3.06	%		$	298,689			$	2,401		3.22	%
Savings and club accounts			133,982				662		1.98	%			141,238				761		2.16	%
Certificates of deposit			754,660				7,296		3.87	%			815,000				8,891		4.36	%
Total interest-bearing deposits			1,235,439				10,610		3.44	%			1,254,927				12,053		3.84	%
Borrowed money			86,151				800		3.71	%			82,712				912		4.41	%
Total interest-bearing liabilities			1,321,590				11,410		3.45	%			1,337,639				12,965		3.88	%
Non-interest-bearing demand deposit			299,529										274,466
Other non-interest-bearing liabilities			24,773										20,114
Total liabilities			1,645,892										1,632,219
Equity			362,364										334,085
Total liabilities and equity		$	2,008,256									$	1,966,304
Net interest income / interest spread						$	24,650		4.06	%						$	25,074		4.23	%
Net interest rate margin									5.14	%									5.35	%
Net interest earning assets		$	598,009									$	538,136
Average interest-earning assets to interest-bearing liabilities			145.25	%									140.23	%

NORTHEAST COMMUNITY BANCORP, INC. NET INTEREST MARGIN ANALYSIS (Unaudited)
		Six Months Ended June 30, 2026										Six Months Ended June 30, 2025
		Average				Interest			Average			Average				Interest			Average
		Balance				and dividend			Yield			Balance				and dividend			Yield
		(In thousands, except yield/cost information)										(In thousands, except yield/cost information)
Loan receivable gross		$	1,825,651			$	70,216		7.69	%		$	1,761,069			$	73,622		8.36	%
Securities			45,234				643		2.84	%			37,298				500		2.68	%
Federal Home Loan Bank stock			473				14		5.92	%			418				16		7.66	%
Other interest-earning assets			55,251				1,156		4.18	%			88,277				2,108		4.78	%
Total interest-earning assets			1,926,609				72,029		7.48	%			1,887,062				76,246		8.08	%
Allowance for credit losses			(4,661	)									(4,978	)
Non-interest-earning assets			92,237										96,071
Total assets		$	2,014,185									$	1,978,155
Interest-bearing demand deposit		$	334,730			$	5,105		3.05	%		$	286,726			$	4,846		3.38	%
Savings and club accounts			134,899				1,332		1.97	%			140,077				1,491		2.13	%
Certificates of deposit			806,181				15,575		3.86	%			888,136				19,649		4.42	%
Total interest-bearing deposits			1,275,810				22,012		3.45	%			1,314,939				25,986		3.95	%
Borrowed money			67,710				1,233		3.64	%			41,584				922		4.43	%
Total interest-bearing liabilities			1,343,520				23,245		3.46	%			1,356,523				26,908		3.97	%
Non-interest-bearing demand deposit			287,324										272,680
Other non-interest-bearing liabilities			23,389										19,107
Total liabilities			1,654,233										1,648,310
Equity			359,952										329,845
Total liabilities and equity		$	2,014,185									$	1,978,155
Net interest income / interest spread						$	48,784		4.02	%						$	49,338		4.11	%
Net interest rate margin									5.06	%									5.23	%
Net interest earning assets		$	583,089									$	530,539
Average interest-earning assets to interest-bearing liabilities			143.40	%									139.11	%